Google Übersetzer
Alnylam Pharmaceuticals, Inc.
About
293.28USD+7.01 +2.45%
Closed • Updated at 19:42 GMT+00:00Market Cap$39.16B
P/E Ratio69.68
Volume397.3K
Beta0.61
RSI43.65
Gross Margin80.83%
Alnylam Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 15 2026
ULTOMIRIS Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
May 12 2026
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
May 7 2026
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
May 6 2026
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 4 2026
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Recent Videos
알나일람, 매출 53억 달러 돌파 예고! 노바티스·로슈가 점찍은 ‘유전자 침묵’ 기술의 압도적 위력
May 13, 2026
Q1FY2026 Alnylam Pharmaceuticals (ALNY) stock | 70% revenue growth in FY26 | Result discussion
May 04, 2026
First 1 Billion $ Quarter! Alnylam Pharmaceutical (Stock ALNY) Amvuttra, Zilebesiran #biotechstocks
May 03, 2026
Transthyretin Cardiac Amyloidosis: Integrating New Paradigms Into Cardiology Practice
Apr 22, 2026